Clonal deletion of T lymphocytes against host organ by early post-transplant cyclophosphamide: clinical study of GVHD prophylaxis in HLA-haploidentical bone marrow transplantation

Clonal deletion of T lymphocytes against host organ by early post-transplant cyclophosphamide: clinical study of GVHD prophylaxis in HLA-haploidentical bone marrow transplantation - HLA-haploidentical BMT using post-transplant CY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009517

Enrollment

Registered

2012-12-12

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies and malignant solid tumors

Interventions

Administration of CY at day 3 after BMT.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Macro/micro residual disease after conventional treatment. Or, relapse after allogeneic HSCT. 2. Written consent was obtained.

Exclusion criteria

Exclusion criteria: 1. Having a severe complication (NCI-CTCAE ver3.0 Grade II or more). 2. Having an uncontrolled infection. 3. Physician's decision.

Design outcomes

Primary

Measure	Time frame
Rate and severity of acute GVHD.	—

Secondary

Measure	Time frame
Engraftment, adverse events, relapse rate, event-free survival. (Monitoring of chronic GVHD)	—

Countries

Japan

Contacts

Public ContactAkihisa SAWADA

Osaka medical center and research institute for maternal and child health Hematology/Oncology

asawada@mch.pref.osaka.jp0725-56-1220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026